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Summary Verapamil had previously been shown to increase cellular melphalan uptake and cytotoxicity in
fibrosarcomas, and increased the area under the blood concentration versus time curve (AUC) for melphalan
in CBA mice. Verapamil (10mgkg-1 i.p.) had no effect on the fractional distribution of cardiac output
(FDCO), measured with 86Rb-rubidium chloride, to subcutaneous fibrosarcomas. 14C-Melphalan uptake by
FS13 fibrosarcomas was increased 60min after verapamil (10mgkg1 i.p.), but not after lower doses which
did not affect the AUC. Flunarizine (5mgkg-I i.p.) also had no effect on FDCO to FS13 fibrosarcomas, and
tended to increase 14C-melphalan content of blood and the fibrosarcomas and to promote growth delay by
melphalan. Alcohol increased FDCO to FS13 fibrosarcomas, maximally at a 1:20 dilution in saline, but had
no effect on 14C-melphalan uptake or growth delay. Thus, melphalan cytotoxicity correlated with tumour
melphalan uptake, and both followed changes in the AUC for melphalan but not changes in FDCO. In these
murine fibrosarcomas melphalan uptake and cytotoxicity were not limited by blood flow.
In subcutaneous human melanoma HX46 xenografts, verapamil had no effect on the FDCO, nor on 14C-
melphalan uptake, and did not affect blood 14C-melphalan levels, suggesting absence of effects on the AUC
and on cellular uptake. Alcohol did not increase the FDCO to HX46 xenografts, providing evidence for a
different vascular supply.
The response rate to melphalan has been increased
by the administration of high intravenous doses
with autologous bone marrow rescue and priming
(Hedley et al., 1978; McElwain et al., 1979;
Cornbleet et al., 1983). However, further dose
escalation is limited by gastrointestinal toxicity
(Millar et al., 1978b,c) and other ways of increasing
the antitumour effect are being sought. Delivery of
most cytotoxic agents to tumours is thought to be
at least partly flow-limited and hence able to be
increased by increasing blood flow (Nugent & Jain,
1984). The calcium antagonists, verapamil and
flunarizine, increased the blood flow to rat
mammary carcinomas, measured using radio-
labelled microspheres (Kaelin et al., 1982; 1984).
These agents decreased vascular resistance more in
the tumour than in the host vessels, so that so long
as blood pressure was maintained, tumour blood
flow was enhanced. However, inhibition of platelet
aggregation (Honn et al., 1985; Tsuruo et al., 1985),
and inhibition of hypoxia-induced vasoconstriction
and reduced red cell deformability (Van Nueten &
Vanhoutte, 1981), were thought to play a part
(Kaelin et al., 1982; 1984). Effects on tumour drug
uptake or cytotoxicity were not studied.
Verapamil enhanced the cytotoxicity ofmelphalan
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to two subcutaneous murine fibrosarcomas
(Robinson et al., 1985), due both to an affect on
melphalan pharmacokinetics in mice and to
enhancement of cellular melphalan uptake. The
evidence that the effect of verapamil was not due to
increased blood flow to the fibrosarcomas is now
presented, along with the results in subcutaneous
human melanoma HX46 xenografts. Furthermore,
the effects of verapamil on in vivo 14C-melphalan
uptake by the fibrosarcomas and xenografts were
studied, and related to growth delay. The effects of
flunarizine were compared with those of verapamil
in the fibrosarcomas.
Materials and Methods
Animals and tumours
Male and female CBA/ca mice were maintained in
the Institute of Cancer Research (ICR) and used
when at least 12 weeks old, weight 20g (females)
and 25-30g (males). Two benzpyrene-induced
fibrosarcomas obtained from Dr S. Eccles (ICR)
were passaged every 2-3 weeks in female CBA
mice. Finely minced tumour was incubated 1 h at
37°C in PBS containing 0.5mgml- pronase,
0.2mgml-1 DNAse and 0.2mgml-i collagenase;
the disaggregated cells were washed in PBS, and
0.6 x 106 cells in 0.1 ml injeCted s.c. into each flank.
Most experiments used bilateral FS13 fibro-
sarcomas, passages 5-12, at 2 weeks, but some used
FS12 (passages 12-15).
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The human melanoma HX46 xenograft was
implanted as 1-2mm pieces subcutaneously in male
CBA mice, immunosuppressed by thymectomy and
9Gy total body irradiation from a 60Co-cobalt
source, preceded 48h by cytosine arabinoside
200mgkg-1 by i.p. injection (Millar et al., 1978a;
Steel et al., 1978). Passages 5-7 were used, 3 weeks
after implantation, a human karyotype demon-
strated through passage 7 (Selby et al., 1980).
Drugs and isotopes
Melphalan (Alkeran, Burrough's Wellcome), alone
or with 14C-melphalan (SRI International, 14C in
chloroethyl side chain, specific activity
33.7pCimg-1), was dissolved in acid alcohol
(5MHCl:ethanol 1:50), usually 20mgml-1, and
stored below 0°C. Immediately before
administration, melphalan was diluted in saline,
acid alcohol:saline 1:20 (aa 1:20), except where
stated. 86Rb-rubidium chloride (Amersham Inter-
national, specific activity 1-8mCimg-1) was
diluted in saline to 30-50 pCiml-1. Verapamil
hydrochloride (Cordilox, Abbott) was diluted in
saline. Flunarizine and placebo (gifts of Janssen
Pharmaceutical) which contained ethanol
39.5mgml-1, mannitol 45mgml-1 and lactic acid
3.2mgml-1, in the presence or absence of
flunarizine 1 mgml-1, were diluted in saline 1:1
and protected from light.
Uptake of86Rb-rubidium chloride
The fractional distribution of cardiac output
(FDCO) to tumours and tissues in CBA mice was
determined using 86Rb-rubidium chloride, in a
method adapted from Sapirstein (1958) and Zanelli
& Fowler (1974). Unanaesthetised mice were given
86Rb, a weighed dose of 3-5pCi in 0.1ml saline,
i.v. through the tail vein, flushed with 0.1 ml saline,
and were killed 60sec later with 0.2ml saturated
potassium chloride i.v. The mice were
exsanguinated from the neck to standardise residual
blood; tumours, liver, heart, kidneys, proximal
small intestine (jejunum), quadriceps muscles,
femurs and a segment of skin excised and weighed.
These tissues, tail, i.v. needle and tubing were
counted in double-walled glass tubes, with weighed
dose standards, for 10 min in a gamma-counter
(Kontron). Counts in the tail and tubing were
subtracted from the dose to correct for extra-
vasation. Mice with more than 20% 86Rb dose in
the tail, and tumours weighing <40 mg were
excluded. The FDCO, as % doseg 1 wet tissue was
expressed as mean+s.e. for groups of at least 5
mice, and of at least 10 tumours, and compared by
Student's t test. Treated and control mice were
studied alternately to allow for possible circadian
variations.
Uptake of14C-melphalan
Groups of at least 5 tumour-bearing mice were
treated with 14C-melphalan, usually 10mgkg-1 i.p.,
with verapamil or saline i.p., and killed up to 4h
later. The mice were bled from the neck under ether
anaesthesia, and the tumours and jejunum excised
and weighed. The 14C content of blood (l00p1) and
tissues was determined using a Packard Oxidiser
306 (United Technologies Packard); 14C was
trapped in 9-10ml Carbosorb, added to 13ml
Permafluor V (Packard) and counted with dose
standards in a liquid scintillation counter
(Intertechnique). 14C-melphalan was expressed as
% dose or pg ml-l blood or g1 wet tissue, and
means+s.e. compared by t test.
Tumour growth delay
Mice were divided into treatment and control
groups of at least 5 mice with bilateral tumours.
Tumour volume was calculated from V=irDd2/6
where D is the longest diameter and d the
perpendicular diameter, measured with calipers.
Volume, as a ratio of volume on the day of
treatment, was plotted against time, and doubling
time obtained. Treatment groups were compared by
applying the 2-tailed Mann-Witney U test to
individual tumour doubling times.
Results
Uptake of 86Rb byfibrosarcomas
The 86Rb content of FS12 and FS13 fibrosarcomas,
and of heart, kidney, jejunum, liver, muscle, skin
and femur in unanaesthetised CBA mice, was
constant from 15 to 90sec after 86Rb administration
(Robinson, 1985), as required for validity of the
method (Sapirstein, 1958). The FDCO to the
fibrosarcomas decreased with increase in weight, as
demonstrated for FS13 in Figure 1, which shows
the data as mean values for control tumours from
24 experiments. The correlation coefficient for
weight and 86Rb uptake of individual FS13
fibrosarcomas was r= -0.5272, P<0.001 (n =269),
and for FS12 fibrosarcomas, r= -0.4283, P<0.002
(n=59). Intravenous or i.p. administration of a
volume of saline equivalent to that of a vasoactive
agent did not itself affect the FDCO (Robinson,
1985).
Effect ofverapamil on tumour FDCO
Blood pressure would have been the best guide to
dose of verapamil, but could not be measured in
unanaesthetised mice. The dose of 10mgkg-1 i.p.
verapamil was selected because it caused a
detectable (0.5°C) but not excessive fall in mouseVERAPAMIL, BLOOD FLOW AND MELPHALAN UPTAKE 609
FS 13 i.p. (n = 13) compared with control 4.49+0.99
6] (n= 10). wlo 11- >;1 c1 W iIen verapamiii /. Mg Kg was giveu i.v.,
FDCO to FS13 fibrosarcomas decreased from 3.69
+0.30% doseg'1 (n=14) in controls to 2.99+0.15
(n = 12) (P <0.05). Verapamil 2.5mgkg-1 i.v. caused
a 1°C fall in mouse temperature, the same fall as
15mgk.g1 i.p., reflecting the 6-8 fold greater
'a 2- , > ' '+ 'potency of i.v. than oral or i.p. verapamil because of
-0 first pass hepatic metabolism (Stone et al., 1980).
Presumably 2.5mgkg-1 i.v. caused hypotension
thereby reducing tumour perfusion.
0- | In the human melanoma HX46 xenografts,
02 04 06 08 verapamil lOmgkg i.p. also had no effect on the
Tumour weight (g) FDCO (Figure2b). Similar changes occurred in
FDCO to normal tissues as in the mice with
Figure 1 Uptake of 86Rb by FS13 fibrosarcomas fibrosarcomas. The values for 86Rb were lower
versus tumour weight, means+s.e. of control mice because of the greater weight of the male mice.
from 24 experiments.
Effect ofalcohol on tumour FDCO
FS 13
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Figure 2 Effect of verapamil 10mgkg-1 i.p. on
FDCO to FS13 fibrosarcomas (a), human melanoma
HX46 xenografts (b) and tissues in CBA mice, at
20min (Jej.=jejunum; verapamil shaded; 5 or 6 mice,
10 tumours; *P<0.005, **P<001, ***P<0.001).
rectal temperature with a nadir at 20min, compared
with saline. Verapamil 15mgkg-1 i.p. caused a 1°C
fall, while 5mgkg-1 i.p. had no effect. The effect of
verapamil lOmgkg- 1 i.p. on FDCO to FS13
fibrosarcomas is shown in Figure 2a. Twenty
minutes after verapamil, the FDCO was decreased
to kidney and skin, and increased to jejunum.
Despite evidence of a vasoactive effect FDCO to
the fibrosarcomas did not change. A similar result
obtained for FS12 fibrosarcomas, with 86Rb uptake
4.26 0.70% doseg-1 after verapamil 10mgkg-1
Mice treated with 10mgkg- 1 melphalan as
routinely diluted from 20mgml-1 in acid alcohol
solvent, received acid alcohol:saline 1:20 (aa 1:20),
10mlkg-'. This solvent increased FDCO to the
FS13 fibrosarcomas, as did ethanol:saline 1:20,
whether given i.p. or i.v. (Table I). The increase in
FDCO to the FS13 fibrosarcomas was dose-related
and was greatest 20min after i.p. administration of
aa 1:20, an increase also occurring after aa 1:10
(Table I). In contrast, alcohol had no effect on the
FDCO to the human melanoma HX46 xenografts,
aa 1:20 lOmlkg-1 resulting in 86Rb uptake of 2.08
+0.26% doseg-1 (n= 11) compared with 1.82+0.21
(n= 10) in controls.
Effect ofalcohol on tumour '4C-melphalan uptake
and growth delay
Uptake of 14C-melphalan by FS13 fibrosarcomas
was determined 60min after i.p. administration in
Table I Effect of acid alcohol solvent for melphalan on
86Rb uptake by murine fibrosarcomas at 20 minutes
Tumour 86Rb (% doseg'1)
Treatment, route
(JOmlkg ') Control (no.) Treated (no)
aa 1:20, i.p. 2.96+0.20 (22) 4.40+0.21 (22)C
ethanol 1:20, i.p. 3.75+0.27 (11) 5.61+0.52 (10)b
aa 1:20, i.v. 5.05 +0.23 (10)C
melphalan in 3.56+0.21 (26) 4.32+0.26 (26)a
aa 1:20, i.p.
aa 1:50, i.p. 2.96+0.20 (10) 3.51 +0.33 (10)
aa 1:20, ip. 4.23 +0.56 (8)a
aa 1:10, i.p. 3.87+0.35 (10)a
aa 1:5, i.p. 3.16+0.18 (10)
aP<0.05, bp<0.01, CP<0.001, compared with control.
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Table II Uptake of 14C-melphalan by FS13 fibro-
sarcomas 60min after 5mgkg-1 i.p. in different solvent
concentrations.
'4C-melphalan
14C-melphalan
solvent Tumour (pgg- )(no.) Blood (jigml- 1)(no.)
aa 1:50 2.2+0.2 (12) 1.7+0.1 (6)a
aa 1:20 2.4+0.1 (12) 2.2+0.1 (6)
aa 1:5 2.5+0.2 (12) 2.2+0.2 (6)
ap<0.05 compared with aa 1:20.
solvent concentrations aa 1:5, aa 1:20 and aa 1:50
(Table II). There was a small decrease in blood 14C-
melphalan after aa 1:50 of doubtful significance, but
no differences in tumour "4C-melphalan uptake.
The solvent had no effect on growth delay of the
FS13 fibrosarcomas; melphalan 7mgkg-1 i.p.
administered with aa 1:50 prolonged the doubling
time 2 days compared with aa 1:20 (P>0.10,
Mann-Witney U test). Therefore the acid alcohol
solvent appeared to affect neither 60min melphalan
uptake, the area under the blood concentration
time curve (AUC), nor cytotoxicity in the
fibrosarcomas.
Effect ofverapamil on tumour 14C-melphalan uptake
The '4C-melphalan content of FS13 fibrosarcomas
30 and 60min (2 experiments) and 4h after
treatment with melphalan 10mgkg-1 i.p., with
saline or verapamil 10mgkg- 1 i.p., is shown in
Figure 3. Uptake of 14C-melphalan by the fibro-
sarcomas was significantly increased at 60min, by
factors of 1.35 and 1.36 in the 2 experiments.
Verapamil 10mgkg- 1 i.p. increased the AUC for
14C-melphalan given i.p. or i.v. to CBA mice
(Robinson et al., 1985), with peak blood levels at
30min, and significantly greater levels after
verapamil from 15min for at least 2h. The dose of
Jejunum 14C-melphalan
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CD 0 5-
E-U,
0)0.-
I 0
Tumour "4C-melphalan FS 13
7 --
'Z 6
*
*
=' 0.4-
.C cj
0 0.2-
n-0
30 min 60 min
Figure 3 Effect of verapamil 10mgkg-1 i.p. on `C-
melphalan uptake by FS13 fibrosarcomas and jejunum,
after 10mgkg-' i.p. (Verapamil shaded; 2 experiments
at 60min; 5-6 mice, 10-12 tumours; ***P<0.001).
verapamil which had no effect on the AUC,
2.5mgkg-
' i.p. (Robinson et al., 1985), had no
effect on '4C-melphalan content of FS13 fibro-
sarcomas although there was a small effect on
blood 14C-melphalan at 60min in this experiment
(Table III). The increase in tumour 14C-melphalan
after verapamil 10 mgkg- 1 i.p. was confirmed in
this experiment.
Verapamil 2.5mgkg-' i.v., which reduced FDCO
to FS13 fibrosarcomas, had no effect on `C-
Table III Effect of verapamil on 14C-melphalan content of tumours and
blood 60min after i.p. administration of melphalan to CBA mice
Tumour 14C-MEL Blood 14C-MEL
(oo dose g-1) (% dose ml-1)
Verapamil
Tumour (No.) mgkg-1 Saline Verapamil Saline Verapamil
FS13 (14) 2.5, i.p. 2.2+0.1 2.3+0.2 2.2+0.2 2.8+0.2a
10, i.p. 2.9+0.1 3.7+0.2
FS13 (12) 2.5, i.v. 2.6+0.2 2.6+0.1 2.2+0.2 2.5+0.1
HX46 (12) 10, i.p. 2.3+0.2 2.0+0.2 2.3+0.1 2.8+0.3
MEL, melphalan
ap<0.05; bP<O.OOl, compared witW salinecouLtrols. by .VERAPAMIL, BLOOD FLOW AND MELPHALAN UPTAKE 611
melphalan content of either the fibrosarcomas or
blood (Table III). In a separate experiment,
verapamil 2.5mgkg- i.v. had had no effect on
the AUC for "4C-melphalan administered i.p.
(Robinson, 1985).
The human melanoma HX46 xenografts showed
no change in '4C-melphalan content with verapamil
10mgkg-' i.p., at 60min (Table III), but a
significant increase in blood 14C-melphalan did not
occur. It is possible that the effects of verapamil on
melphalan pharmacokinetics were somehow
modified in these irradiated mice.
Effect offlunarizine on tumour FDCO and
"4C-melphalan uptake
Flunarizine, another calcium antagonist and
vasodilator, had no significant effect on the FDCO
to FS13 fibrosarcomas when 5mgkg-1 were given
i.p. (Table IV). Placebo, providing the equivalent of
aa 1:50, lOmlkg-1 i.p., also had no effect on
FDCO, but tumour blood flow was significantly
lower after flunarizine than placebo. Flunarizine
and placebo had no significant effects on FDCO to
normal tissues except for a small increase in FDCO
to muscle after flunarizine. Mice with FS13
fibrosarcomas were treated with '4C-melphalan 5
mgkg- 1 i.p. with aa 1:50 solvent, with either saline,
placebo or flunarizine 5mgkg- 1 i.p. (Table IV).
(Mice treated with placebo or flunarizine received
twice the dose of ethanol compared with controls,
total just less than aa l:20, but this should not
affect the result because tumour 14C-melphalan was
the same for aa 1:50 and aa 1:20 (Table II).) Sixty
minutes after flunarizine, blood 14C-melphalan was
increased compared with placebo treatment but not
compared with saline, and the increase in tumour
14C-melphalan was not significant (Table IV).
Effect of verapamil andflunarizine on growth delay
by melphalan
Verapamil 10mgkg- 1 i.p. promoted the growth
delay by melphalan for FS12 and FS13 fibro-
sarcomas, with a greater effect in FS12, the less
sensitive tumour (Robinson et al., 1985). Verapamil
2.5mgkg-i.p., which had no effect on AUC or
tumour uptake of melphalan, had no modifying
effect on growth delay of FS13 fibrosarcomas by
melphalan (Table V). Verapamil 10mgkg-1 i.p.
enhanced growth delay in the HX46 xenografts, but
to a smaller extent than in the fibrosarcomas.
Verapamil 10mgkg-1 i.p. alone had no effect on
the growth of either the fibrosarcomas or the HX46
Table IV Effect of flunarizine on FDCO and "4C-melphalan uptake of FS13
fibrosarcomas
Saline Placebo Flunarizine
1Omlkg-1 i.p. lOmlkg-1 i.p. 5mgkg-' i.p.
Tumour 86Rb (% dose g-') 3.91+0.32 4.58+0.28 3.38+0.21a
No. tumours 14 13 14
Tumour 14C-melphalan (ugg-) 3.8+0.3 3.5+0.3 4.1 +0.3
No. tumours 12 12 12
Blood 14C-melphalan (ugml-') 2.7+0.4 2.5+0.3 3.4+0.3b
ap<0.001 compared with placebo; bp<0.05, compared with placebo; 86Rb at 15min,
14C-melphalan at 60min.
Table V Effect of verapamil and flunarizine on growth delay by melphalan in
fibrosarcomas and human melanoma HX46 xenografts
Vasoactive agent
g.d. by MEL g.d. (agent+MEL)
10mgkg- 1 i.p. Dose
Tumour (days) Name (mgkg'-) (days) ratioa
FS13 15 Verapamil 2.5, i.p. 11 0.7
FS13 1lb Flunarizine 5, i.p. 13 1.3+
HX46 13c Verapamil 10, i.p. 17 1.3+ +
g.d.=growth delay; MEL=melphalan.
aRatio of g.d. by melphalan+vasoactive agent/g.d. by melphalan; bMelphalan
given with placebo; cMelphalan dose 7.5mgkg- ' i.p.; +a<0.10, + +a<0.05, 2-
tailed Mann-Witney U test, compared with g.d. by melphalan.612 B.A. ROBINSON et al.,
xenografts. Flunarizine had a small enhancing effect
on growth delay in the fibrosarcomas (Table V).
Discussion
Verapamil 10mgkg-1 i.p. had no effect on the
relative blood flow (FDCO, measured with 86Rb)
to subcutaneous murine fibrosarcomas, and
increased 14C-melphalan uptake 60min after
administration, previous work having shown
verapamil to potentiate growth delay by melphalan
in these fibrosarcomas and to increase the AUC of
melphalan (Robinson et al., 1985). Verapamil
2.5 mg kg-1 i.p., which had not affected the AUC
(Robinson et al., 1985), had no effect on tumour
melphalan uptake nor cytotoxicity. Verapamil
2.5mgkg-1 i.v., equivalent to about 15-20mgkg-1
i.p. because of first pass hepatic metabolism (Stone
et al., 1980), decreased FDCO to the fibrosarcomas
but had no effect on either tumour uptake or the
AUC of melphalan. The effects of flunarizine
resembled those of verapamil on fibrosarcoma
FDCO, melphalan uptake and growth delay, but
were less marked. Alcohol increased the FDCO to
the fibrosarcomas, but when administered as
melphalan solvent, had no effect on melphalan
uptake and cytotoxicity, nor on the AUC. For
melphalan, changes in cytotoxicity followed changes
in tumour uptake, and reflected changes in the
AUC but not in tumour blood flow.
The subcutaneous human melanoma HX46
xenografts differed from the fibrosarcomas in
showing no increase in 14C-melphalan content after
verapamil 10mgkg-1 i.p., but no increase in AUC
occurred and verapamil enhanced the growth delay
of HX46 by melphalan in a different experiment.
The xenografts showed no change in FDCO after
verapamil, but in contrast to the fibrosarcomas,
FDCO did not increase after the acid alcohol
solvent. The latter finding suggests a difference in
vascular supply, possibly intrinsic to the xenografts
or resulting from total body irradiation prior to
implantation (Clifton & Jirtle, 1975).
Verapamil potentiation of cellular melphalan
uptake by the fibrosarcomas, described previously
(Robinson et al., 1985), probably contributed to the
enhanced in vivo melphalan uptake and cyto-
toxicity, because of the correlation between
enhanced cellular uptake and growth delay for
FS12 and FS13 (Robinson et al., 1985). The lack of
a fall in tumour 14C-melphalan despite the decrease
in FDCO to fibrosarcomas, without any change in
AUC, after verapamil 2.5mgkg-1 i.v., might be
explained by enhanced cellular melphalan uptake,
or by the absence of limitation of melphalan uptake
by blood flow. The small potentiation of growth
delay in HX46 might be due to an effect on the
AUC of melphalan, which was not significant in
the experiment in Table III, or perhaps due to an
effect on cellular melphalan uptake. Unfortunately
it was not possible to measure the effect of
verapamil on melphalan uptake by HX46 cells in
vitro (Robinson et al., 1985). However if the AUC
was unaffected, as in Table III, enhanced cellular
melphalan uptake might have occurred.
Although melphalan was measured as 14C-
melphalan, total 14C-melphalan correlated with
parent melphalan and with 14C-melphalan bound
to cellular macromolecules including DNA in other
tumours (Brown et al., 1980; Furner & Brown,
1980), and verapamil had no effect on melphalan
hydrolysis (Robinson et al., 1985). The vascular
volume of the fibrosarcomas was 1.4% (14 l g-1),
determined using 59Fe-labelled red cells (Robinson,
1985), making it unlikely that changes in tumour
14C-melphalan content were due to changes in the
14C-melphalan concentration of blood within the
tumour. In mice, verapamil might affect melphalan
pharmacokinetics by increasing absorption or
retarding renal clearance, through enhanced
jejunum and decreased renal blood flow (see
Figure 2). In man, oral verapamil increased renal,
hepatic and splanchnic flow, after the first dose
(Meredith et al., 1985), and little net effect on
melphalan pharmacokinetics might be expected,
depending on the relative contributions of these
organs. Verapamil 10mgkg-1 i.p. in mice both had
cardiovascular effects and increased tumour
melphalan uptake, perhaps suggesting potential for
similar tumour effects at safe cardiovascular doses
in man.
Alcohol was the only vasodilator to increase
blood flow to the fibrosarcomas; verapamil,
flunarizine, epoprostenol and phentolamine failed
(Robinson, 1985). Most other vasodilators also
did not increase blood flow to experimental
tumours, including phenoxybenzamine, isoprenaline,
papaverine and hydralazine (Jirtle et al., 1978;
Debreczeni et al., 1980; Mattsson et al., 1982; Chan
et al., 1984). Tumour perfusion depends on the
relative vascular resistance of the tumour and host
circulations and on systemic blood pressure (Chan
et al., 1984; Suzuki et al., 1984). Only doses of
verapamil and flunarizine which reduced tumour
vascular resistance without reducing blood pressure
increased tumour blood flow (Kaelin et al., 1982;
1984) and the associated change in tumour FDCO
would have been detectable by 86Rb. Discrepancies
have been reported in the FDCO derived from the
distribution of microspheres, used by Kaelin et al.
(1982; 1984), and of 86Rb in unanaesthetised rats
(Foster & Frydman, 1978). These arise from the
anatomical and functional differences of various
capillary beds (Mendell and Hollenberg, 1971)VERAPAMIL, BLOOD FLOW AND MELPHALAN UPTAKE 613
which make the assumption (Sapirstein, 1958) that
every tissue has the same extraction ratio for 86Rb
not strictly true (Appelgren, 1979). In mice,
microspheres cannot be used and 86Rb is accepted
as a valid indicator of capillary flow (Zanelli &
Fowler, 1974; Zanelli et al., 1975; Wetterlin et al.,
1977; Appelgren, 1979). However, inability to
measure cardiac output and blood pressure in mice
makes adjustment of vasodilator dose difficult.
Tumour melphalan uptake was not limited by
blood flow, with no increase in uptake when FDCO
was increased by alcohol. The 14C-melphalan
content of FS13 fibrosarcomas at 60min increased
with tumour weight (Robinson, 1985), in contrast
to the decrease in FDCO, suggesting that with time
melphalan reached even poorly perfused regions.
This is supported by 14C-melphalan autoradio-
graphy, which showed radioactivity throughout
histologically viable and necrotic regions of FS13
fibrosarcomas after 1 h (Robinson, 1985).
Distribution of 14C-misonidazole was limited by
flow only in very poorly perfused parts of sub-
cutaneous sarcomas in rats (Blasberg et al., 1985).
Thus, for these experimental tumours, blood flow
does not limit melphalan uptake, but agents such as
verapamil which increase cellular melphalan
transport (Robinson et al., 1985) increase cyto-
toxicity. However, for tumours with very low blood
flow, as is the case in many human tumours where
flows as low as 1/30 that of surrounding normal
tissue have been recorded (Shibata & MacLean,
1966), or for cytotoxic drugs cleared more rapidly
from the blood than melphalan, drug uptake may
be limited by blood flow and be increased by
vasoactive agents such as alcohol, or angiotensin II
(Robinson, 1985). The equivalent dose of ethanol
to humans receiving high-dose melphalan i.v. would
be less than I of that in mice given aa 1:20i.v., and
could safely be increased in man if ethanol was
found to increase blood flow to some human
tumours (of which xenografts in irradiated mice
may not be representative) and if drug uptake by
them was flow-limited.
It was concluded that in the subcutaneous murine
fibrosarcomas and human melanoma HX46
xenografts, tumour melphalan uptake was not
limited by blood flow, and that cytotoxicity
correlated with tumour melphalan uptake, both
changing with the AUC for melphalan and with
verapamil enhancement of cellular melphalan
uptake.
The authors would like to thank Mr E. Merryweather and
his staff for care of the animals, Miss R. Couch for typing
the manuscript, and the Nuffield Foundation and the
Royal Marsden Hospital for support of BAR.
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